The US Court of Appeals for the Federal Circuit (CAFC) issued its decision upholding the validity of US Patent No 9,187,405 covering a dosing regimen for Gilenya (fingolimod), Swiss pharma giant Novartis’ (NOVN: VX) blockbuster multiple sclerosis treatment, the company announced today.
In August 2020, the US Federal District Court for the District of Delaware issued a favorable decision in the Gilenya patent litigation and a permanent injunction was granted against China-based HEC Pharma (HKG: 1558) until the expiration of the ‘405 patent in December 2027 (including pediatric exclusivity). HEC Pharma was the only remaining Abbreviated New Drug Application (ANDA) filer challenging this patent. This decision confirms the validity of the patent and allows that injunction to remain in place.
Previously, Novartis entered into settlement agreements with a number of ANDA filers. Those ANDA filers will not be able to launch a generic version of Gilenya, if approved by the Food and Drug Administration, before an agreed upon date that is prior to the expiration of the dosage regimen patent in December 2027. The potential generic entry date and other terms of the settlement agreement are confidential.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze